{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:52:00Z","timestamp":1789426320259,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100005977","name":"Kaiser Permanente","doi-asserted-by":"publisher","award":["Community Benefit Grant"],"award-info":[{"award-number":["Community Benefit Grant"]}],"id":[{"id":"10.13039\/100005977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,8,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Data guiding the duration and route of streptococcal bloodstream infection (BSI) treatment are lacking. We conducted a retrospective cohort study of adults hospitalized with uncomplicated streptococcal BSI in a large integrated healthcare system from 2013 to 2020. The exposures of interest were antibiotic duration (5\u201310 days vs. 11\u201315 days) and antibiotic route (oral switch vs. entirely intravenous). The primary outcome was a composite 90-day outcome comprised of all-cause mortality, recurrent streptococcal BSI, or readmission. We performed non-inferiority analyses for each exposure. Separate multivariable Cox proportional hazards regression models were constructed for each exposure. The antibiotic duration analysis included 1,407 patients (5\u201310 days,\n              <jats:italic>n<\/jats:italic>\n              = 246; 11\u201315 days,\n              <jats:italic>n<\/jats:italic>\n              = 1,161). We found that 5\u201310-day courses were non-inferior to 11\u201315-day courses (\n              <jats:italic>P<\/jats:italic>\n              = 0.047). The antibiotic route analysis included 1,461 patients (oral switch,\n              <jats:italic>n<\/jats:italic>\n              = 1,112; entirely intravenous,\n              <jats:italic>n<\/jats:italic>\n              = 349). Oral step-down therapy did not meet the criteria for non-inferiority (\n              <jats:italic>P<\/jats:italic>\n              = 0.06). In the adjusted models, no significant difference was found in the primary outcome rate by antibiotic duration or antibiotic route at discharge. We found that 5\u201310-day courses were non-inferior to longer courses, and thus may be a safe and effective treatment option in the treatment of uncomplicated streptococcal bacteremia. Randomized controlled trials are needed to confirm the equivalent outcomes with shorter regimens and to definitively determine the optimal antibiotic route on discharge.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00220-24","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:01:03Z","timestamp":1720443663000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Antibiotic duration and route for treatment of adults with uncomplicated streptococcal bloodstream infections: a retrospective study in a large healthcare system"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-7022","authenticated-orcid":true,"given":"Dana S.","family":"Clutter","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Kaiser Permanente South San Francisco Medical Center, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Samiezade-Yazd","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila H.","family":"Champsi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Kaiser Permanente South San Francisco Medical Center, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schapiro","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California Regional Laboratory, Berkeley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12144"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12195"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2024"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6226"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.07.016"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001393"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.05.011"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix767"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir301"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0195-6701(98)90019-6"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.19.2588"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3640"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.1938"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.01.027"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.9.1159"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2017.167"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1542\/hpeds.2018-0193"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221101105"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710926"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411162"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1054"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.07.013"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.12.015"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1449"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1445"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1472"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1475"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1471"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.838"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2097"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106736"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/653065"},{"key":"e_1_3_4_35_2","unstructured":"Services USDoHaH Administration FaD Research CfDEa. 2018. Complicated urinary tract infections: developing drugs for treatment guidance for industry. Available from: https:\/\/www.fda.gov\/media\/71313\/download"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.6.848"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.028"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01515-20"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00220-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00220-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T13:04:35Z","timestamp":1723035875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00220-24"}},"subtitle":[],"editor":[{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,7]]}},"alternative-id":["10.1128\/aac.00220-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00220-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"2024-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00220-24"}}